Stimulant use disorder (StUD), particularly involving cocaine and amphetamines, is associated with significant cognitive impairments that impede recovery and increase relapse risk. Atomoxetine, a selective norepinephrine reuptake inhibitor, has been proposed as a potential treatment given its role in enhancing executive function and its established efficacy in attention-deficit/hyperactivity disorder (ADHD). This systematic review aimed to evaluate the efficacy, cognitive, and mood effects of atomoxetine compared with placebo in individuals with StUD.
Methods:
A comprehensive literature search of PubMed, Cochrane CENTRAL, and Embase databases was conducted to identify randomized controlled trials (RCTs) evaluating atomoxetine for StUD. Eligible studies compared atomoxetine with placebo and assessed outcomes related to cognition (attention and response inhibition), stimulant use or abstinence, mood symptoms, and safety. Data were extracted and synthesized qualitatively due to methodological heterogeneity across studies.
Results:
Nine RCTs met the inclusion criteria. Findings on cognitive outcomes were inconsistent: Some studies reported improvements in attentional bias and inhibitory control, while others showed no significant effects. Atomoxetine did not significantly reduce stimulant use, craving, or sustain abstinence compared with placebo. Limited mood-related benefits were observed, particularly among male participants, although results were variable. Across studies, atomoxetine was well tolerated, with most adverse events mild and transient.
Conclusion:
Despite a compelling neurobiological rationale and evidence of modest cognitive and mood benefits, atomoxetine has not demonstrated consistent efficacy as a monotherapy for StUD. Its favorable safety profile may warrant further investigation in carefully defined populations, such as individuals with comorbid ADHD or in combination with behavioral interventions.
FarrellMMartinNKStockingsE, et al. Responding to global stimulant use: challenges and opportunities. Lancet. 2019;394(10209):1652-1667. doi:10.1016/S0140-6736(19)32230-5
2.
DegenhardtLBaxterAJLeeYY, et al. The global epidemiology and burden of psychostimulant dependence: findings from the Global Burden of Disease Study 2010. Drug Alcohol Depend. 2014;137:36-47. doi:10.1016/j.drugalcdep.2013.12.025
3.
AlexanderPDGicasKMWilliTS, et al. A comparison of psychotic symptoms in subjects with methamphetamine versus cocaine dependence. Psychopharmacology (Berl). 2017;234(9-10):1535-1547. doi:10.1007/s00213-017-4551-7
4.
CallaghanRCHallidayMGatleyJ, et al. Comparative hazards of acute myocardial infarction among hospitalized patients with methamphetamine- or cocaine-use disorders: a retrospective cohort study. Drug Alcohol Depend. 2018;188:259-265. doi:10.1016/j.drugalcdep.2018.03.030
5.
HavakukORezkallaSHKlonerRA.The cardiovascular effects of cocaine. J Am Coll Cardiol. 2017;70(1):101-113. doi:10.1016/j.jacc.2017.05.014
6.
CepedaJAVickermanPBruneauJ, et al. Estimating the contribution of stimulant injection to HIV and HCV epidemics among people who inject drugs and implications for harm reduction: a modeling analysis. Drug Alcohol Depend. 2020;213:108135. doi:10.1016/j.drugalcdep.2020.108135
7.
TanzLJMillerKDDinwiddieAT, et al. Drug overdose deaths involving stimulants—United States, January 2018-June 2024. MMWR Morb Mortal Wkly Rep. 2025;74(32):491-499. doi:10.15585/mmwr.mm7432a1
8.
The ASAM/AAAP Clinical practice guideline on the management of stimulant use disorder. J Addict Med. 2024;18(1S):1-56. doi:10.1097/ADM.0000000000001299
LondonEDGromanSMLeytonMDe WitH.The mesocorticolimbic system in stimulant use disorder. Mol Psychiatry. 2025;30(11):5486-5499. doi:10.1038/s41380-025-03148-0
11.
WeeSWoolvertonWL.Evaluation of the reinforcing effects of atomoxetine in monkeys: comparison to methylphenidate and desipramine. Drug Alcohol Depend. 2004;75(3):271-276. doi:10.1016/j.drugalcdep.2004.03.010
12.
YeRMazibukoNTeichertJRegenthalRKehagiaAAMehtaMA.Mapping the effects of atomoxetine during response inhibition across cortical territories and the locus coeruleus. Psychopharmacology (Berl). 2022;239(2):365-376. doi:10.1007/s00213-021-05998-2
13.
BarbutiMMaielloMSperaV, et al. Challenges of treating ADHD with comorbid substance use disorder: considerations for the clinician. J Clin Med. 2023;12(9):3096. doi:10.3390/jcm12093096
14.
BusheCJSavillNC.Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009–2011: focus on clinical efficacy and safety. J Psychopharmacol (Oxf). 2014;28(3):204-211. doi:10.1177/0269881113478475
15.
BrancatiGEMagnesaAAciernoD, et al. Current nonstimulant medications for adults with attention-deficit/hyperactivity disorder. Expert Rev Neurother. 2024;24(8):743-759. doi:10.1080/14737175.2024.2370346
16.
ClemowDBusheCManciniMOssipovMUpadhyayaH.A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities. Neuropsychiatr Dis Treat. 2017;13:357-371. doi:10.2147/NDT.S115707
17.
KhoodoruthMASOuanesSKhanYS. A systematic review of the use of atomoxetine for management of comorbid anxiety disorders in children and adolescents with attention-deficit hyperactivity disorder. Res Dev Disabil. 2022;128:104275. doi:10.1016/j.ridd.2022.104275
18.
PageMJMcKenzieJEBossuytPM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
19.
CantilenaLKahnRDuncanCCLiSHAndersonAElkashefA.Safety of atomoxetine in combination with intravenous cocaine in cocaine-experienced participants. J Addict Med. 2012;6(4):265-273. doi:10.1097/ADM.0b013e31826b767f
20.
DeVitoEEHermanAIKonkusNSZhangHSofuogluM.Atomoxetine in abstinent cocaine users: sex differences. Data Brief. 2017;14:566-572. doi:10.1016/j.dib.2017.08.011
21.
DeVitoEEHermanAIKonkusNSZhangHSofuogluM.Atomoxetine in abstinent cocaine users: cognitive, subjective and cardiovascular effects. Pharmacol Biochem Behav. 2017;159:55-61. doi:10.1016/j.pbb.2017.07.002
22.
OlivetoA. Clinical Efficacy of Atomoxetine for Methamphetamine Dependence (ATM). University of Arkansas; 2017. Accessed June 5, 2025. https://clinicaltrials.gov/study/NCT01557569
23.
RabieyAHassani-AbharianPFarhadMMoravvejiARAkashehGBanafsheHR.Atomoxetine efficacy in methamphetamine dependence during methadone maintenance therapy. Arch Iran Med. 2019;22(12):692-698.
24.
WalshSLMiddletonLSWongCJ, et al. Atomoxetine does not alter cocaine use in cocaine dependent individuals: a double blind randomized trial. Drug Alcohol Depend. 2013;130(1-3):150-157. doi:10.1016/j.drugalcdep.2012.10.024
25.
SchottenfeldRSChawarskiMCSofuogluM, et al. Atomoxetine for amphetamine-type stimulant dependence during buprenorphine treatment: a randomized controlled trial. Drug Alcohol Depend. 2018;186:130-137. doi:10.1016/j.drugalcdep.2018.01.017
26.
NestorLJLuijtenMZiauddeenH, et al. The modulatory effects of atomoxetine on aberrant connectivity during attentional processing in cocaine use disorder. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024;9(3):314-325. doi:10.1016/j.bpsc.2023.08.003
27.
PassamontiLLuijtenMZiauddeenH, et al. Atomoxetine effects on attentional bias to drug-related cues in cocaine dependent individuals. Psychopharmacology (Berl). 2017;234(15):2289-2297. doi:10.1007/s00213-017-4643-4
28.
ZhukovskyPMorein-ZamirSZiauddeenH, et al. Prefrontal cortex activation and stopping performance underlie the beneficial effects of atomoxetine on response inhibition in healthy volunteers and those with cocaine use disorder. Biol Psychiatry Cogn Neurosci Neuroimaging. 2022;7(11):1116-1126. doi:10.1016/j.bpsc.2021.08.010
29.
CorteseS.Pharmacologic treatment of attention deficit–hyperactivity disorder. Ropper AH, ed. N Engl J Med. 2020;383(11):1050-1056. doi:10.1056/NEJMra1917069
30.
MarianiJJLevinFR.Psychostimulant treatment of cocaine dependence. Psychiatr Clin North Am. 2012;35(2):425-439. doi:10.1016/j.psc.2012.03.012
31.
CastellsXCunillRPérez-MañáCVidalXCapellàD.Psychostimulant drugs for cocaine dependence. Cochrane Drugs and Alcohol Group, ed. Cochrane Database Syst Rev. 2016;2016(9). doi:10.1002/14651858.CD007380.pub4
32.
AndersonALReidMSLiSH, et al. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend. 2009;104(1-2):133-139. doi:10.1016/j.drugalcdep.2009.04.015
33.
KampmanKMPettinatiHLynchKG, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend. 2004;75(3):233-240. doi:10.1016/j.drugalcdep.2004.03.008
34.
DutraLStathopoulouGBasdenSLLeyroTMPowersMBOttoMW.A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry. 2008;165(2):179-187. doi:10.1176/appi.ajp.2007.06111851
35.
De CrescenzoFCiabattiniMD’AlòGL, et al. Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: a systematic review and network meta-analysis. Degenhardt L, ed. PLOS Med. 2018;15(12):e1002715. doi:10.1371/journal.pmed.1002715
36.
VolkowNDFowlerJSWangGJSwansonJM.Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry. 2004;9(6):557-569. doi:10.1038/sj.mp.4001507
37.
KoobGFVolkowND.Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016;3(8):760-773. doi:10.1016/S2215-0366(16)00104-8
38.
SofuogluMMooneyM.Cholinergic functioning in stimulant addiction: implications for medications development. CNS Drugs. 2009;23(11):939-952. doi:10.2165/11310920-000000000-00000
39.
DwoskinLP.Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse. 1st ed. Elsevier; 2014.
40.
Van Emmerik-van OortmerssenKVan De GlindGVan Den BrinkW, et al. Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis. Drug Alcohol Depend. 2012;122(1-2):11-19. doi:10.1016/j.drugalcdep.2011.12.007
41.
MichelsonDFariesDWernickeJ, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108(5):e83. doi:10.1542/peds.108.5.e83
42.
KonovaABMoellerSJTomasiDVolkowNDGoldsteinRZ.Effects of methylphenidate on resting-state functional connectivity of the mesocorticolimbic dopamine pathways in cocaine addiction. JAMA Psychiatry. 2013;70(8):857. doi:10.1001/jamapsychiatry.2013.1129
43.
LeydeSTilhouASTsuiJI.Methamphetamine use disorder. JAMA. 2025;334(13):1192. doi:10.1001/jama.2025.12007
44.
AshokAHMizunoYVolkowNDHowesOD.Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: a systematic review and meta-analysis. JAMA Psychiatry. 2017;74(5):511. doi:10.1001/jamapsychiatry.2017.0135
WolraichMLHaganJFAllanC, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144(4):e20192528. doi:10.1542/peds.2019-2528
47.
StringfieldSJKirschmannEKTorregrossaMM.Working memory performance predicts, but does not reduce, cocaine and cannabinoid seeking in adult male rats. Int J Neuropsychopharmacol. 2024;27(10):pyae048. doi:10.1093/ijnp/pyae048
48.
RonsleyCNolanSKnightR, et al. Treatment of stimulant use disorder: a systematic review of reviews. Hashimoto K, ed. PLOS ONE. 2020;15(6):e0234809. doi:10.1371/journal.pone.0234809
49.
RayLAMeredithLRKilukBDWalthersJCarrollKMMagillM.Combined pharmacotherapy and cognitive behavioral therapy for adults with alcohol or substance use disorders: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(6):e208279. doi:10.1001/jamanetworkopen.2020.8279
50.
PerugiGPallucchiniARizzatoS, et al. Pharmacotherapeutic strategies for the treatment of attention-deficit hyperactivity (ADHD) disorder with comorbid substance-use disorder (SUD). Expert Opin Pharmacother. 2019;20(3):343-355. doi:10.1080/14656566.2018.1551878
51.
SkoglundCBrandtLD’OnofrioBLarssonHFranckJ.Methylphenidate doses in attention deficit/hyperactivity disorder and comorbid substance use disorders. Eur Neuropsychopharmacol. 2017;27(11):1144-1152. doi:10.1016/j.euroneuro.2017.08.435
52.
FarhatLCFloresJMBehlingE, et al. The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis. Mol Psychiatry. 2022;27(3):1562-1572. doi:10.1038/s41380-021-01391-9
53.
ClemowDBBusheCJ.Atomoxetine in patients with ADHD: a clinical and pharmacological review of the onset, trajectory, duration of response and implications for patients. J Psychopharmacol (Oxf). 2015;29(12):1221-1230. doi:10.1177/0269881115602489
54.
SavillNCBuitelaarJKAnandE, et al. The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of clinical research. CNS Drugs. 2015;29(2):131-151. doi:10.1007/s40263-014-0224-9
55.
WietechaLAClemowDBBuchananASYoungJLSarkisEHFindlingRL.Atomoxetine increased effect over time in adults with attention-deficit/hyperactivity disorder treated for up to 6 months: pooled analysis of two double-blind, placebo-controlled, randomized trials. CNS Neurosci Ther. 2016;22(7):546-557. doi:10.1111/cns.12533
56.
KilukBDCarrollKMDuhigA, et al. Measures of outcome for stimulant trials: ACTTION recommendations and research agenda. Drug Alcohol Depend. 2016;158:1-7. doi:10.1016/j.drugalcdep.2015.11.004
